ALMRAlamar Biosciences, Inc.
Alamar Biosciences, Inc. (ALMR) sells proteomics and biomarker testing tools for clinical research and diagnostics. The next catalyst is Nov 3, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to scale its proteomics platform and sustain revenue growth after a recent earnings miss.
- ALMR has a narrow revenue base, with $84.72M in revenue for the 10-Q period ending 2026-06-30, but operates with a steep net loss of -$62.87M.
- Free cash flow has been negative for the trailing twelve months, and the company is still burning through equity.
- The business relies on high-margin clinical validation and university partnerships to drive long-term adoption of its proteomics platform.
The Read
4% after announcing a major university partnership for a national proteomics initiative and strong clinical validation, then rose another 16.
The schedule
- Tue3Nov
This earnings release will test the company's ability to deliver on its guidance and provide clarity on its cash runway and clinical progress. The outcome will be critical for assessing the company's ability to maintain its current valuation and attract investor confidence.
- Wed9Dec
The company is likely to explore equity financing options during this period, which could signal either a need for liquidity or a strategic move to fund new initiatives. The market will be watching for any signs of a capital raise and its potential impact on the stock.
- Mon4Jan
This update will provide insight into the company's clinical progress and the potential of its proteomics platform. The market will be looking for any positive data or strategic announcements that could drive the stock higher.
- Tue12Jan
- Sat30Jan
This earnings release will provide a comprehensive view of the company's performance for the full year 2026. The market will be looking for any signs of improved financials, operational efficiency, or strategic progress that could justify the current valuation.
- Sat1May
This earnings release will provide a comprehensive view of the company's performance for the first quarter of 2027. The market will be looking for any signs of improved financials, operational efficiency, or strategic progress that could justify the current valuation.
- Wed12May
This conference presentation will provide insight into the company's strategic direction, financial outlook, and potential partnerships. The market will be looking for any signs of a clear roadmap or positive developments that could drive the stock higher.
- Fri6Aug
This earnings release will provide a comprehensive view of the company's performance for the second quarter of 2027. The market will be looking for any signs of improved financials, operational efficiency, or strategic progress that could justify the current valuation.
Past
- Tue6Oct
Actual outcome: Bear · $25.92 at outcome
ALMR experienced a sharp decline due to a significant earnings miss and downward guidance, which signaled weaker-than-expected performance and reduced future growth prospects. The company likely reported lower-than-anticipated revenue and profit, prompting investors to reassess its valuation and future outlook. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -13.9% from 2026-10-06 to 2026-10-08 (~2.5σ vs typical 1d vol). Target evaluation date 2026-10-11 (not yet reached as of 2026-10-08). Confidence 95%.
ALMR experienced a sharp decline due to a significant earnings miss and downward guidance, which signaled weaker-than-expected performance and reduced future growth prospects. The company likely reported lower-than-anticipated revenue and profit, prompting investors to reassess its valuation and future outlook. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -13.9% from 2026-10-06 to 2026-10-08 (~2.5σ vs typical 1d vol). Target evaluation date 2026-10-11 (not yet reached as of 2026-10-08). Confidence 95%.
- Fri7Aug
Actual outcome: Bull · $29.90 at outcome
Alamar Biosciences reported Q2 2026 revenue of $29.4M, up 82% YoY, driven by strong consumables growth and expanded biomarker panels. The company also launched the NULISAseq Immune 340 Panel, enhancing its position in precision proteomics and driving investor confidence, which led to a significant price increase despite an EPS miss.
With ALMR trading within 5% of its 52-week high, Q2 earnings face a high bar. A -$20.3M quarterly operating cash flow against a $64.5M cash pile brings dilution fears forward.